Novo Nordisk Issues Troubling 2026 Guidance, Stock Plummets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Source: NASDAQ.COM
- Stock Plunge: Novo Nordisk's stock has lost over 50% of its value in the past 12 months, trading at just 10 times earnings, reflecting extreme market pessimism regarding its future performance and severely undermining investor confidence.
- 2026 Guidance Cut: The company projects a revenue decline of up to 13% for the current year, despite launching a new Wegovy pill, as management faces pricing pressures and must lower prices to attract customers and gain market share, impacting future growth potential.
- Partnership with Hims & Hers: Novo Nordisk has reached an agreement with telehealth company Hims & Hers to sell its GLP-1 products on their platform, which could provide new momentum for sales growth following the release of its troubling guidance, potentially improving performance.
- Long-term Investment Opportunity: Despite current challenges, Novo Nordisk's low valuation offers a good margin of safety for long-term investors; renowned investor Warren Buffett has noted his preference for investing in companies facing
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 42.920
Low
42.00
Averages
54.67
High
70.00
Current: 42.920
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches Wegovy in UAE, Expanding Global Reach
- International Expansion: Novo Nordisk has launched its weight loss pill Wegovy in the UAE, marking its first entry into a market outside the U.S., which signifies a strategic move to enhance its global presence and competitiveness.
- Demand-Driven Approach: The decision to launch is guided by patient demand, readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure, indicating a cautious yet adaptable strategy for entering new markets.
- Strong Market Momentum: Emil Kongshøj Larsen, EVP of International Operations, highlighted that the UAE has shown strong momentum in these areas, suggesting an increasing acceptance and demand for new medications, which could lead to significant sales growth for the company.
- Future Market Plans: Novo Nordisk aims to introduce Wegovy to additional select countries in the coming months, a strategy that not only helps expand its market share globally but also lays the groundwork for long-term growth opportunities.
See More
Novo Nordisk Faces Competitive Pressures in Weight Management Market
- Increased Market Competition: Novo Nordisk's leadership in the anti-obesity drug market is challenged by Eli Lilly's Zepbound, which demonstrated superior weight-loss efficacy in clinical trials, leading to a decline in Novo Nordisk's market share and negatively impacting its stock performance.
- Clinical Trial Setbacks: The company's next-generation weight-loss drug, CagriSema, failed to meet management's projected 25% mean weight loss target and proved inferior to Zepbound in head-to-head trials, raising concerns about the future viability of its product pipeline.
- Financial Guidance Downgrades: Due to a loss of share in the GLP-1 market, Novo Nordisk has had to lower its financial guidance for 2025 multiple times, with expectations of revenue decline for fiscal year 2026, reflecting the significant challenges the company faces.
- New Product Development Outlook: Despite these challenges, Novo Nordisk's launch of an oral formulation of Wegovy has attracted a large number of new patients, and the development of new drugs like Amycretin and UBT251 may enhance its market position and fend off competition.
See More
Eli Lilly Leads Weight Loss Market with Zepbound and Retatrutide
- Significant Sales Growth: Eli Lilly's weight management drug Zepbound has surpassed sales of its main competitor Wegovy, establishing the company as a leader in the rapidly growing anti-obesity market, reflecting strong performance and increased market share.
- Clinical Trial Results: The next-generation weight-loss drug retatrutide demonstrated impressive results in phase 3 trials, with patients on the highest dose losing an average of 28.3% of their body weight over 80 weeks, far exceeding the 2.2% loss in the placebo group, indicating its competitive potential and future sales prospects.
- Huge Market Potential: Despite rapid sales growth of Zepbound, Eli Lilly plans to target underserved segments of the weight-loss market with retatrutide, particularly patients with high BMIs, which is expected to further expand its customer base and market share.
- Long-term Investment Value: Eli Lilly's ongoing innovation and diverse product pipeline in the weight-loss sector, combined with strong financial performance, suggest that its stock still has room for growth, making it suitable for long-term investors to hold.
See More
Eli Lilly's Retatrutide Outperforms Zepbound
- Significant Drug Efficacy: Eli Lilly's new drug retatrutide demonstrated remarkable efficacy in clinical trials, with patients on the highest dose losing an average of 28.3% of their body weight over 80 weeks, compared to just 2.2% in the placebo group, indicating its superiority over competitor Zepbound.
- Massive Market Potential: The obesity rate in the U.S. may be as high as 70%, yet only 12% of adults are currently using GLP-1 drugs, revealing a vast untapped market that retatrutide will help Eli Lilly penetrate further.
- Clear Sales Strategy: Eli Lilly plans to target high BMI patients with retatrutide, as 45.3% of participants on the highest dose achieved over 30% weight loss, a result typically seen only after bariatric surgery, indicating strong market demand for this drug.
- Ongoing Innovation Capability: In addition to retatrutide, Eli Lilly has several other candidates in development, showcasing its sustained leadership in the weight-loss sector, which is expected to continue driving strong financial performance.
See More
Viking Therapeutics' VK2735 Phase 3 Trials Outlook
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in Phase 3 trials, with investors hopeful for its efficacy and safety, particularly as it competes against larger rivals Eli Lilly and Novo Nordisk, raising interest in its market share potential.
- Comparative Drug Advantage: In Phase 2 trials, VK2735's injectable form achieved a peak weight loss of 14.7% over 13 weeks, outperforming competitors, which highlights its significant advantage in weight loss speed and may attract more patients.
- Tolerability Challenges: Despite VK2735's strong weight loss results, the oral formulation showed disappointing tolerability with a 20% treatment discontinuation rate, raising concerns about its long-term safety and potentially affecting market acceptance.
- Dual-Formulation Development: VK2735 is also being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking Therapeutics with additional competitive edge, although it still needs to address tolerability issues.
See More
Viking Therapeutics Faces Competitive Challenges in Weight-Loss Market
- Intensifying Market Competition: Viking Therapeutics' VK2735 faces fierce competition in the weight-loss drug market from Eli Lilly and Novo Nordisk, particularly with Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo, which is projected to reach $1.2 billion in sales by 2026, highlighting significant market potential.
- Clinical Trial Progress: VK2735 is currently in Phase 3 trials, and while it demonstrated a 14.7% weight loss in Phase 2, the oral formulation showed poor tolerability with a 20% treatment discontinuation rate due to adverse events, which may hinder its market acceptance.
- Dual-Formulation Advantage: VK2735 is being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking with a crucial market share advantage in a competitive landscape.
- Uncertain Future Outlook: Although bulls hope that Phase 3 trials will demonstrate better tolerability and weight loss results, Viking must overcome its lag behind two larger rivals to secure a foothold in the weight-loss drug market.
See More
Novo Nordisk Launches Wegovy in UAE, Expanding Global Reach
- International Expansion: Novo Nordisk has launched its weight loss pill Wegovy in the UAE, marking its first entry into a market outside the U.S., which signifies a strategic move to enhance its global presence and competitiveness.
- Demand-Driven Approach: The decision to launch is guided by patient demand, readiness of healthcare professionals, and the strength of healthcare and telehealth infrastructure, indicating a cautious yet adaptable strategy for entering new markets.
- Strong Market Momentum: Emil Kongshøj Larsen, EVP of International Operations, highlighted that the UAE has shown strong momentum in these areas, suggesting an increasing acceptance and demand for new medications, which could lead to significant sales growth for the company.
- Future Market Plans: Novo Nordisk aims to introduce Wegovy to additional select countries in the coming months, a strategy that not only helps expand its market share globally but also lays the groundwork for long-term growth opportunities.
See More
Novo Nordisk Faces Competitive Pressures in Weight Management Market
- Increased Market Competition: Novo Nordisk's leadership in the anti-obesity drug market is challenged by Eli Lilly's Zepbound, which demonstrated superior weight-loss efficacy in clinical trials, leading to a decline in Novo Nordisk's market share and negatively impacting its stock performance.
- Clinical Trial Setbacks: The company's next-generation weight-loss drug, CagriSema, failed to meet management's projected 25% mean weight loss target and proved inferior to Zepbound in head-to-head trials, raising concerns about the future viability of its product pipeline.
- Financial Guidance Downgrades: Due to a loss of share in the GLP-1 market, Novo Nordisk has had to lower its financial guidance for 2025 multiple times, with expectations of revenue decline for fiscal year 2026, reflecting the significant challenges the company faces.
- New Product Development Outlook: Despite these challenges, Novo Nordisk's launch of an oral formulation of Wegovy has attracted a large number of new patients, and the development of new drugs like Amycretin and UBT251 may enhance its market position and fend off competition.
See More
Eli Lilly Leads Weight Loss Market with Zepbound and Retatrutide
- Significant Sales Growth: Eli Lilly's weight management drug Zepbound has surpassed sales of its main competitor Wegovy, establishing the company as a leader in the rapidly growing anti-obesity market, reflecting strong performance and increased market share.
- Clinical Trial Results: The next-generation weight-loss drug retatrutide demonstrated impressive results in phase 3 trials, with patients on the highest dose losing an average of 28.3% of their body weight over 80 weeks, far exceeding the 2.2% loss in the placebo group, indicating its competitive potential and future sales prospects.
- Huge Market Potential: Despite rapid sales growth of Zepbound, Eli Lilly plans to target underserved segments of the weight-loss market with retatrutide, particularly patients with high BMIs, which is expected to further expand its customer base and market share.
- Long-term Investment Value: Eli Lilly's ongoing innovation and diverse product pipeline in the weight-loss sector, combined with strong financial performance, suggest that its stock still has room for growth, making it suitable for long-term investors to hold.
See More
Eli Lilly's Retatrutide Outperforms Zepbound
- Significant Drug Efficacy: Eli Lilly's new drug retatrutide demonstrated remarkable efficacy in clinical trials, with patients on the highest dose losing an average of 28.3% of their body weight over 80 weeks, compared to just 2.2% in the placebo group, indicating its superiority over competitor Zepbound.
- Massive Market Potential: The obesity rate in the U.S. may be as high as 70%, yet only 12% of adults are currently using GLP-1 drugs, revealing a vast untapped market that retatrutide will help Eli Lilly penetrate further.
- Clear Sales Strategy: Eli Lilly plans to target high BMI patients with retatrutide, as 45.3% of participants on the highest dose achieved over 30% weight loss, a result typically seen only after bariatric surgery, indicating strong market demand for this drug.
- Ongoing Innovation Capability: In addition to retatrutide, Eli Lilly has several other candidates in development, showcasing its sustained leadership in the weight-loss sector, which is expected to continue driving strong financial performance.
See More
Viking Therapeutics' VK2735 Phase 3 Trials Outlook
- Clinical Trial Progress: Viking Therapeutics' VK2735 is currently in Phase 3 trials, with investors hopeful for its efficacy and safety, particularly as it competes against larger rivals Eli Lilly and Novo Nordisk, raising interest in its market share potential.
- Comparative Drug Advantage: In Phase 2 trials, VK2735's injectable form achieved a peak weight loss of 14.7% over 13 weeks, outperforming competitors, which highlights its significant advantage in weight loss speed and may attract more patients.
- Tolerability Challenges: Despite VK2735's strong weight loss results, the oral formulation showed disappointing tolerability with a 20% treatment discontinuation rate, raising concerns about its long-term safety and potentially affecting market acceptance.
- Dual-Formulation Development: VK2735 is also being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking Therapeutics with additional competitive edge, although it still needs to address tolerability issues.
See More
Viking Therapeutics Faces Competitive Challenges in Weight-Loss Market
- Intensifying Market Competition: Viking Therapeutics' VK2735 faces fierce competition in the weight-loss drug market from Eli Lilly and Novo Nordisk, particularly with Novo Nordisk's oral Wegovy and Eli Lilly's Foundayo, which is projected to reach $1.2 billion in sales by 2026, highlighting significant market potential.
- Clinical Trial Progress: VK2735 is currently in Phase 3 trials, and while it demonstrated a 14.7% weight loss in Phase 2, the oral formulation showed poor tolerability with a 20% treatment discontinuation rate due to adverse events, which may hinder its market acceptance.
- Dual-Formulation Advantage: VK2735 is being developed as a dual-formulation therapy, with Phase 1 trial results expected in Q3; if proven effective, this could provide Viking with a crucial market share advantage in a competitive landscape.
- Uncertain Future Outlook: Although bulls hope that Phase 3 trials will demonstrate better tolerability and weight loss results, Viking must overcome its lag behind two larger rivals to secure a foothold in the weight-loss drug market.
See More
